Stockholders Approve Aggressive Reverse Split to Address Nasdaq Compliance
QNCX sits 18% above its 52-week low of $0.79 on light trading volume (0.1× avg).
Summary
Stockholders approved a highly aggressive reverse stock split (up to 1-for-100) to help Quince Therapeutics maintain its Nasdaq listing, following previous compliance issues and a recent 1-for-10 split.
Key Events · Corporate Governance and Compliance · QNCX
-
Reverse Stock Split Authorized
Stockholders approved an amendment to the certificate of incorporation, authorizing the board to effect a reverse stock split at a ratio ranging from 1-for-10 to 1-for-100. This follows previous efforts to address Nasdaq's minimum bid price requirement.
-
Director Elected
June Bray was elected as a Class I director to the Board of Directors, serving until the 2029 annual meeting.
-
Auditor Ratified
BDO USA, P.C. was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026.
Analysis · QNCX · Life Sciences
Quince Therapeutics' stockholders have authorized the board to implement a reverse stock split at a ratio of up to 1-for-100. This is a critical step for the micro-cap company, which has a history of Nasdaq non-compliance and previously executed a 1-for-10 reverse split in April 2026. The approval provides the company with the necessary flexibility to potentially increase its share price and meet Nasdaq's minimum bid price requirement, thereby avoiding delisting. While necessary for survival, the need for such a drastic measure underscores the company's ongoing challenges.
At the time of this filing, QNCX was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.79 to $45.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.